A Phase 3 interventional study of INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010 in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 32 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 105th largest by enrollment of the 178 interventional ones that give a count, is one of 8 that started in 2019, is one of 80 in phase 3, and was the 169th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 334 across the 178 interventional studies, 1,229 across the 5 observational. Of the 183 that completed or were terminated, 46 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling.
Secondary Objective:
To gain additional information on the efficacy and safety of using a simple patient-titration protocol for administration of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi).
The maximum duration of study per patient is approximately 29 weeks including a 2-week screening, a 26-week randomized active-controlled treatment period, and 3-day post-treatment safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Change in glycated hemoglobin (HbA1c)%
Absolute mean change in HbA1c from baseline to Week 26; HbA1c is expressed in % (unit)
Time frame: Baseline to Week 26
Percentage of patients achieving HbA1c ≤7% at Week 26
Percentage of patients achieving A1c ≤7%
Time frame: At Week 26
Change in fasting plasma glucose (FPG) from baseline to Week 12
Change in FPG from baseline to Week 12
Time frame: Baseline to Week 12
Change in FPG from baseline to Week 26
Change in FPG from baseline to Week 26
Time frame: Baseline to Week 26
Change in fasting self-monitoring plasma glucose (SMPG) from baseline to Week 12
Change in fasting SMPG from baseline to Week 12
Time frame: Baseline to Week 12
Change in fasting SMPG from baseline to Week 26
Change in fasting SMPG from baseline to Week 26
Time frame: Baseline to Week 26
Change in 7-point SMPG profile from baseline to Week 12
Change in 7-point SMPG profile from baseline to Week 12
Time frame: Baseline to Week 12
Change in 7-point SMPG profile from baseline to Week 26
Change in 7-point SMPG profile from baseline to Week 26
Time frame: Baseline to Week 26
Change in body weight from baseline to Week 26
Change in body weight (kg)
Time frame: Baseline to Week 26
Percentage of patients achieving A1c ≤7% with no body weight gain and/or hypoglycemia (severe or documented symptomatic (≤3.9 mmol/L) at Week 26
Composite endpoint expressed as percentage of patients A1c ≤7% with no body weight gain and/or hypoglycemia (severe or documented symptomatic (≤3.9 mmol/L)
Time frame: Baseline to Week 26
Insulin glargine dose
Insulin glargine dose (expressed in units)
Time frame: At Week 26
Percentage of patients requiring rescue therapy
Percentage of patients requiring rescue therapy during the 26-week open-label treatment period
Time frame: Baseline to Week 26
Percentage of patients experiencing at least 1 hypoglycemia episode (≤3.9 mmol/L) over 26 weeks
Percentage of patients experiencing at least 1 hypoglycemia episode defined as ≤3.9 mmol/L
Time frame: Baseline to Week 26
Percentage of patients experiencing at least 1 hypoglycemia episode (<3.0 mmol/L) over 26 weeks
Percentage of patients experiencing at least 1 hypoglycemia episode defined as \<3.0 mmol/L
Time frame: Baseline to Week 26
Annualized rate of hypoglycemia (≤3.9 mmol/L) over 26 weeks
Mean number of hypoglycemia episodes (≤3.9 mmol/L) per patient year of exposure over 1 year
Time frame: Baseline to Week 26
Annualized rate of hypoglycemia (<3.0 mmol/L) over 26 weeks
Mean number of hypoglycemia episodes (\<3.0 mmol/L) per patient year of exposure over 1 year
Time frame: Baseline to Week 26
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2019 to primary completion in Oct 2020, 19 months.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.